Zoetis Servs. LLC v. United States

United States Court of International Trade·Decided September 2, 2026·No. 22-00056·Published

Opinion

Slip Op. 26-102

UNITED STATES COURT OF INTERNATIONAL TRADE

ZOETIS SERVICES LLC

Plaintiff, Before: Joseph A. Laroski, Jr., Judge v.

Court No. 22-00056

UNITED STATES

Defendant.

OPINION

[In a Customs matter regarding classification of feed-grade chlortetracycline concentrate, plaintiff’s motion for summary judgment is granted and defendant’s cross-motion for summary judgment is denied.]

Dated: September, 02, 2026

William R. Rucker, Faegre Drinker Biddle & Reath, LLP of Chicago, IL, argued for plaintiff Zoetis Services LLC.

Marcella Powell, Senior Trial Counsel, International Trade Field Office, Civil Division, U.S. Department of Justice, of Washington, D.C., argued for defendant United States Government. On the brief were Luke Mathers, Trial Attorney Commercial Litigation Branch, Civil Division, U.S. Department of Justice, Brett A. Shumate, Assistant Attorney General, Patricia M. McCarthy, Director, Justin R. Miller, Attorney-In-Charge, International Trade Field Office, and Aimee Lee, Assistant Director. Of counsel, arguing for defendant and on the brief, was Michael A. Anderson, Office of the Assistant Chief Counsel, International Trade Litigation, U.S. Customs and Border Protection.

Laroski, Judge: The actions before the court are cross-motions for summary judgment pursuant to U.S. Court of International Trade (“USCIT”) Rule 56(a). Pl.

Mot. for Sum. J., ECF No. 41 (Mar. 19, 2025) (“Zoetis Br.”); Def. Mem. in Supp. of Cross-Mot. for Sum. J., ECF No. 51 (June 30, 2025) (“Gov. Br.”). Plaintiff Zoetis Services LLC (“Zoetis”) challenges the U.S. Customs and Border Protection’s classification of feed-grade chlortetracycline concentrate under heading 2309 of the Harmonized Tariff Schedule of the United States (“HTSUS”). Zoetis contends that the imported merchandise is an antibiotic under heading 2941 because its only active ingredient is chlortetracycline, a recognized antibiotic, and its inactive ingredients [hereinafter “non-antibiotic substances”] are permissible impurities resulting from the manufacturing process. Zoetis Br. at 1–2. Alternatively, Zoetis argues that the imported merchandise is classifiable as a medicament under heading 3003 given its therapeutic and prophylactic uses. Id. Meanwhile, the Government argues that the imported merchandise should be classified under heading 2309 as a preparation for animal feed. Gov Br. at 2. For the reasons laid out below, the court holds that the imported merchandise is properly classified as an antibiotic under subheading 2941.30.00 which provides for “Antibiotics: Tetracyclines and their derivatives; salts thereof.”

BACKGROUND

I. Procedural Background There are no material facts in dispute in this case. Zoetis Br. at 2; Gov. Br. at 15. The merchandise in question consists of feed-grade chlortetracycline concentrate powder (“CTC-FG”) manufactured in China by Jinhe Biotechnology Co., Ltd. and imported by Zoetis Services LLC (“Zoetis”). Joint Statement of Undisputed

Facts, ECF No. 38, ¶¶ 1, 5 (Mar. 14, 2025) (“JSUF”). Zoetis made two entries at the Port of Chicago, Illinois: one on December 26, 2019, and the other on January 22, 2020. Id. ¶ 1. U.S. Customs and Border Protection (“Customs”) classified the imported merchandise in both entries under subheading 2309.90.10 (2020 ed.)1, a duty-free provision, and assessed Section 301 duties under subheading 9903.88.03 at 25 percent ad valorem. Id. ¶ 2. Zoetis protested Customs’s liquidation and paid all liquidated duties, taxes, and charges. Id. ¶¶ 3–4. Customs denied the protests, and Zoetis filed summonses. Id. ¶ 4. Zoetis commenced this action requesting reliquidation of the imported merchandise under subheading 2941.30.00, or alternatively, under subheading 3003.20.00. Zoetis Br. at 2. The court held oral argument on May 28, 2026.

II. Description of Imported Merchandise CTC-FG is an active pharmaceutical ingredient (“API”) composed of a broad-

spectrum antibiotic, chlortetracycline (also known by the trade name “Aureomycin”). JSUF ¶¶ 5–7.

The production of CTC-FG begins with the biomass fermentation process in which bacteria Streptomyces aureofaciens is “aerobically fermented in an aqueous culture medium” (i.e., a fermentation “broth”) to produce chlortetracycline. Id.

1 The relevant portion of Chapter 23 reads: 2309 (HTSUS 2020)

Preparations of a kind used in animal feeding:

2309.90 Other: 2309.90.10 Mixed feeds or mixed feed ingredients 2309.90.1050 Other

¶¶ 9–10. The fermentation process lasts until the desired chlortetracycline concentration has been reached. Id. ¶ 12. Second, calcium carbonate is mixed into the fermentation broth to create a chlortetracycline calcium complex which stabilizes the product so that it does not degrade when incorporated into animal feed. Pl.’s Statement of Material Facts ¶ 18 (“PSMF”) (citation omitted); Def.’s Resp. to Pl.’s Statement of Material Facts ¶ 18 (“Def. Resp. Facts”). Third, “the entire contents of the fermentation vessel the bacterial colony, the chlortetracycline that it produced, and the remaining culture medium—are filtered and dried.” JSUF ¶ 12. Finally, the dried contents are sieved and ground into a “fine brown powder or granular substance” which Zoetis imports in bulk in 750-kilogram bags. Id. ¶ 14. At importation, the CTC-FG has a chlortetracycline concentration of 23.8 to 24.7 percent, id. ¶¶ 5–6, and includes the following non-antibiotic substances: “mycelial cake, microbial cells, residual nutrients, other fermentation components, and metabolic products.” PSMF ¶ 17; Def. Resp. Facts ¶ 17. The only active ingredient in the imported merchandise is the chlortetracycline. PSMF ¶ 2; Def. Resp. Facts ¶ 2. The imported merchandise “is not a significant source of nutrients for animals,” nor is it directly fed to animals. JSUF ¶ 17–18.

CTC-FG is a “microingredient” which undergoes post-importation processing in order to be added to animal feed. JSUF ¶ 19. After importation, the CTC-FG is used exclusively by Zoetis to manufacture four Type A Medicated Articles. Id. ¶ 20– 21. Zoetis’s Type A Medicated Articles are manufactured by blending the imported merchandise with “multiple diluents, including rice hulls, calcium sulfate, or

calcium carbonate.” Id. ¶ 23. The diluents are “not intended to provide a significant source of nutrition to the animal diet.” Id. ¶ 24. The resulting Type A Medicated Articles have a chlortetracycline concentration ranging between 7.7 and 22 percent. Id. ¶ 25.

The FDA has approved Zoetis’s Type A Medicated Articles for “maintaining the health of livestock (poultry, swine, and cattle), including the treatment, prevention, and control of a wide range of respiratory and enteric diseases, such as bacterial pneumonia, bacterial enteritis, anaplasmosis, and other diseases, as well as aiding in the maintenance of weight gain in the presence of disease.” Id. ¶ 31. Zoetis’s Type A Medicated Articles are labeled and marketed in accordance with their FDA-approved uses. Id. ¶ 32.

Zoetis primarily sells its Type A Medicated Articles to “feed mills, farmers, and manufacturers of Type B Medicated Feed and Type C Medicated Feed articles, . . . for ultimate use in livestock feeds.” Id. ¶ 33. To legally feed the Type B and Type C Medicated Feeds to animals, a licensed veterinarian must issue a veterinary feed directive (“VFD”). Id. ¶ 30.

JURISDICTION AND STANDARD OF REVIEW The court exercises exclusive jurisdiction over “any civil action commenced to contest the denial of a protest, in whole or in part, under section 515 of the Tariff Act of 1930” (“the Act”), as amended. 28 U.S.C. § 1581(a). Actions to contest the denial of a protest are adjudicated by the court de novo, and the court determines the correct classification “upon the basis of the record made before the court.” 28

Free access — add to your briefcase to read the full text and ask questions with AI

Zoetis Servs. LLC v. United States, (cit 2026).

Zoetis Servs. LLC v. United States (Zoetis Servs. LLC v. United States) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Faus Group, Inc. v. United States
581 F.3d 1369 (Federal Circuit, 2009)
Benq America Corp. v. United States
646 F.3d 1371 (Federal Circuit, 2011)
CamelBak Products, LLC v. United States
649 F.3d 1361 (Federal Circuit, 2011)
Jarvis Clark Co. v. United States
733 F.2d 873 (Federal Circuit, 1984)
Mita Copystar America v. United States
21 F.3d 1079 (Federal Circuit, 1994)
Universal Electronics Inc. v. United States
112 F.3d 488 (Federal Circuit, 1997)
Primal Lite, Inc. v. United States
182 F.3d 1362 (Federal Circuit, 1999)
Carl Zeiss, Inc. v. United States
195 F.3d 1375 (Federal Circuit, 1999)
Deckers Outdoor Corp. v. United States
714 F.3d 1363 (Federal Circuit, 2013)
Dependable Packaging Solutions, Inc. v. United States
757 F.3d 1374 (Federal Circuit, 2014)
Roche Vitamins, Inc. v. United States
772 F.3d 728 (Federal Circuit, 2014)
Irwin Industrial Tool Company v. United States
920 F.3d 1356 (Federal Circuit, 2019)
Janssen Ortho LLC v. United States
425 F. Supp. 3d 1352 (Court of International Trade, 2020)
United States v. Carborundum Co.
536 F.2d 373 (Customs and Patent Appeals, 1976)
Orlando Food Corp. v. States
140 F.3d 1437 (Federal Circuit, 1998)